Study identifier:CD-ON-MEDI4736-1161
ClinicalTrials.gov identifier:NCT02027961
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects with Metastatic or Unresectable Melanoma in Combination with Dabrafenib and Trametinib or with Trametinib Alone
Melanoma
Phase 1
No
Dabrafenib, Trametinib
All
68
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Safety
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Mar 2021 by MedImmune, LLC
MedImmune, LLC
-
The purpose of this study is to determine the maximum tolerated dose and characterize the safety profile of durvalumab (MEDI4736) in combination with dabrafenib and trametinib or with trametinib alone in participants with metastatic or unresectable melanoma with BRAF-mutation positive or wild-type (WT) BRAF, respectively.
This is a multicenter, open-label study with a dose escalation phase followed by an expansion phase of durvalumab administered in combination with dabrafenib and trametinib or with trametinib alone in participants with BRAF V600 mutation-positive and WT unresectable or metastatic melanoma, respectively.
Location
Location
Scottsdale, AZ, United States, 85258
Location
Miami Beach, FL, United States, 33140
Location
Los Angeles, CA, United States, 90095
Location
Toronto, ON, Canada, M5G 2M9
Location
Montreal, QC, Canada, H3A 1A1
Location
Boston, MA, United States, 02114
Location
St Louis, MO, United States, 63110
Location
Chicago, IL, United States, 60611
Arms | Assigned Interventions |
---|---|
Experimental: Cohort A1: Durvalumab (3 mg/kg) + Dabrafenib +Trametinib Participants will receive intravenous (IV) dose of 3 milligrams per kilogram (mg/kg) durvalumab every 2 weeks (Q2W) from Day 1 up to 12 months along with oral 150 mg dabrafenib capsule twice daily (BID) and oral 2 mg trametinib tablet once daily (QD) until confirmed disease progression (PD), initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 3 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib. | Biological/Vaccine: Durvalumab Intravenous dose of 3 or 10 mg/kg durvalumab. Drug: Dabrafenib Oral dose of 150 mg dabrafenib capsule. Drug: Trametinib Oral dose of 2 mg trametinib tablet. |
Experimental: Cohort A2: Durvalumab (10 mg/kg) + Dabrafenib +Trametinib Participants will receive IV dose of 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral doses of dabrafenib 150 mg capsule BID and trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib. | Biological/Vaccine: Durvalumab Intravenous dose of 3 or 10 mg/kg durvalumab. Drug: Dabrafenib Oral dose of 150 mg dabrafenib capsule. Drug: Trametinib Oral dose of 2 mg trametinib tablet. |
Experimental: Cohort B: Durvalumab (10 mg/kg) +Trametinib (Concurrent) Participants will receive concurrent doses of IV 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral dose of trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of trametinib. | Biological/Vaccine: Durvalumab Intravenous dose of 3 or 10 mg/kg durvalumab. Drug: Trametinib Oral dose of 2 mg trametinib tablet. |
Experimental: Cohort C: Durvalumab (10 mg/kg) +Trametinib (Sequential) Participants will receive sequential doses of oral trametinib tablet 2 mg QD from Day 1 to Day 42 and IV durvalumab 10 mg/kg Q2W starting from Day 29 (Week 5) up to 12 months. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months. | Biological/Vaccine: Durvalumab Intravenous dose of 3 or 10 mg/kg durvalumab. Drug: Trametinib Oral dose of 2 mg trametinib tablet. |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.